merck 3rd qtr sales of isentress just released yesterday
ISENTRESS (raltegravir), Merck's first-in-class HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, reported worldwide sales of $197 million for the third quarter of 2009, an increase of 84 percent compared with the third quarter 2008.
so we have for the nrti sales
ftc 2.4B
tdf 2.6B
3tc 1.0B
atc ???
and catching up with next year >$1B
isentress 0.8B
- Forums
- ASX - By Stock
- AVX
- atc sales
atc sales, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
MTL
Mantle Minerals' Nick Poll talks to HotCopper on finding gold grades up to 3.57g/t at Mt Berghaus
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated